ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
January 02, 2019 07:00 ET
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
December 20, 2018 16:01 ET
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease
December 19, 2018 08:06 ET
|
Small Logo
LA JOLLA, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
September 12, 2018 09:30 ET
|
FibroGen, Inc
SAN FRANCISCO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
August 06, 2018 13:00 ET
|
Nohla Therapeutics
SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
July 31, 2018 08:30 ET
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
May 29, 2018 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
HighQ featured in Sunday Times’ Lloyds SME Export Track 100
February 27, 2018 14:19 ET
|
HighQ
LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- HighQ has again earned distinction in Fast Track’s Sunday Times Lloyds SME Export Track 100, which tracks Britain’s small- and medium-sized private...
ARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
January 08, 2018 08:30 ET
|
ARCA biopharma, Inc.
-------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial...
ARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial
August 16, 2017 08:30 ET
|
ARCA Biopharma, Inc.
GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018 WESTMINSTER,...